

## Author Index

## A

Adler, L.E., and Waldo, M.C. Counterpoint: A sensory gating—hippocampal model of schizophrenia, 17(1):19-24, 1991.

Amador, X.F.; Strauss, D.H.; Yale, S.A.; and Gorman, J.M. Awareness of illness in schizophrenia, 17(1):113-132, 1991.

an der Heiden, W.; *see* Häfner, H.

Andreasen, N.C. Assessment issues and the cost of schizophrenia, 17(3):475-481, 1991; Reply to "Phenomenology or physicalism?", 17(2):187-189, 1991; Schizophrenia and related disorders in *DSM-IV*: Editor's introduction, 17(1):25-26, 1991; *see also* Flaum, M.

Andreasen, N.C., and Flaum, M. Schizophrenia: The characteristic symptoms, 17(1):27-49, 1991.

Andrews, G. The cost of schizophrenia revisited, 17(3):389-394, 1991.

Angermeyer, M.C.; Kühn, L.; and Goldstein, J.M. Gender and the course of schizophrenia: Differences in treated outcomes, 16(2):293-307, 1990.

Anonymous. First person account: A pit of confusion, 16(2):355-359, 1990; First person account: Behind the mask: A functional schizophrenic copes, 16(3):547-549, 1990; First person account: Birds of a psychic feather, 16(1):165-168, 1990.

Appelbaum, P.S.; *see* Cassens, G.

Aravagiri, M.; *see* Van Putten, T.

## B

Bardenstein, K.K.; *see* McGlashan, T.H.

Bartels, S.J.; Drake, R.E.; Wallach, M.A.; and Freeman, D.H. Characteristic hostility in schizophrenic outpatients, 17(1):163-171, 1991.

Bartko, J.J. Measurement and reliability: Statistical thinking considerations, 17(3):483-489, 1991.

Bassett, A.; *see* Weeks, D.E.

Battaglia, M.; Gasperini, M.; Sciuto, G.; Scherillo, P.; Diaferia, G.; and Bellodi, L. Psychiatric disorders in the families of schizotypal subjects, 17(4):659-668, 1991.

Beaudett, M.S.; *see* Drake, R.E.

Beecham, J.; Knapp, M.; and Fenyo, A. Costs, needs, and outcomes, 17(3):427-439, 1991.

Bellack, A.S.; *see* Mueser, K.T.

Bellodi, L.; *see* Battaglia, M.

Benes, F.M.; Sorensen, I.; and Bird, E.D. Reduced neuronal size in posterior hippocampus of schizophrenic patients, 17(4):597-608, 1991.

Benson, D.F., and Stuss, D.T. Frontal lobe influences on delusions: A clinical perspective, 16(3):403-411, 1990.

Bird, E.D.; *see* Benes, F.M.

Blaska, B. First person account: What it is like to be treated like a CMI, 17(1):173-176, 1991.

Bleuler, M. Seasonality of birth of future schizophrenics and seasonality of depressive episodes (Letter to the Editor), 17(2):191-192, 1991.

Bowers, M.B., Jr.; *see* Lieberman, J.A.

Bowers, M.B., Jr.; Mazure, C.M.; Nelson, J.C.; and Jatlow, P.I. Psychotogenic drug use and neuroleptic response, 16(1):81-85, 1990.

Bowler, A.E.; *see* Torrey, E.F.

Bracha, H.S. Etiology of structural asymmetry in schizophrenia: An alternative hypothesis (Letter to the Editor), 17(4):551-553, 1991.

Braff, D.L.; *see* Butler, R.W.

Brenner, H.D.; Dencker, S.J.; Goldstein, M.J.; Hubbard, J.W.; Keegan, D.L.; Kruger, G.; Kulhanek, F.; Liberman, R.P.; Malm, U.; and Midha, K.K. Defining treatment refractoriness in schizophrenia, 16(4):551-561, 1990.

Brown, C.H.; *see* Pulver, A.E.

Brzustowicz, L.; *see* Weeks, D.E.

**Buchsbaum, M.S.** Frontal lobes, basal ganglia, temporal lobes—Three sites for schizophrenia?, 16(3):377-378, 1990; The frontal lobes, basal ganglia, and temporal lobes as sites for schizophrenia, 16(3):379-389, 1990.

**Burke, S.S.**; *see* Test, M.A.

**Burns, T.**, and Raftery, J. Cost of schizophrenia in a randomized trial of home-based treatment, 17(3):407-410, 1991.

**Butler, R.W.**, and Braff, D.L. Delusions: A review and integration, 17(4):633-647, 1991.

### C

**Caldwell, C.B.**, and Gottesman, I.I. Schizophrenics kill themselves too: A review of risk factors for suicide, 16(4):571-589, 1990.

**Caldwell-Smith, G.** First person account: A mother's view, 16(4):687-690, 1990.

**Capri, S.**; *see* Moscarelli, M.

**Carlsson, A.**; *see* Carlsson, M.

**Carlsson, M.**, and Carlsson, A. Schizophrenia: A subcortical neurotransmitter imbalance syndrome?, 16(3):425-432, 1990.

**Cassens, G.**; Inglis, A.K.; Appelbaum, P.S.; and Gutheil, T.G. Neuroleptics: Effects on neuropsychological function in chronic schizophrenic patients, 16(3):477-499, 1990.

**Centifanti, J.B.**; *see* Rogers, J.A.

**Chabert, N.**; *see* Van Putten, T.

**Childers, S.E.**, and Harding, C.M. Gender, premorbid social functioning, and long-term outcome in *DSM-III* schizophrenia, 16(2):309-318, 1990.

**Christison, G.W.**; Kirch, D.G.; and Wyatt, R.J. When symptoms persist: Choosing among alternative somatic treatments for schizophrenia, 17(2):217-245, 1991.

**Clark, C.**; *see* Kopala, L.

**Clarkin, J.F.**; *see* Haas, G.L.

**Coffman, J.A.**; *see* Nasrallah, H.A.

**Copolov, D.L.**; *see* McGorry, P.D. **Cornblatt, B.**; *see* Weeks, D.E.

**Costa, J.**; *see* Jin, Y.

**Crow, T.J.** Temporal lobe asymmetries as the key to the etiology of schizophrenia, 16(3):433-443, 1990.

### D

**Dalén, P.** Does age incidence explain all season-of-birth effects in the literature?, 16(1):11-12, 1990; Is the familial/sporadic subdivision a method of genetics?, 16(3):363-365, 1990.

**de Girolamo, G.**; *see* Sartorius, N.

**Dencker, S.J.**; *see* Brenner, H.D.

**Diaferia, G.**; *see* Battaglia, M.

**Dixon, L.**; *see* Haas, G.; Weiden, P.;

*Sweeney, J.*; and *Frances, A.*

Acute effects of drug abuse in schizophrenic patients: Clinical observations and patients' self-reports, 16(1):69-79, 1990.

**Dobscha, S.K.**; *see* Hoffman, R.E.

**Docherty, N.M.**; *see* Harvey, P.D.

**Dossetor, C.R.**; *see* McGorry, P.D.

**Douglas, M.S.**; *see* Mueser, K.T.

**Drake, R.E.**; *see* Bartels, S.J.

**Drake, R.E.**; *see* Osher, F.C.; Noordsy, D.L.; Hurlbut, S.C.; Teague, G.B.; and Beaudett, M.S. Diagnosis of alcohol use disorders in schizophrenia, 16(1):57-67, 1990.

**Dworkin, R.H.**; *see* Lenzenweger, M.F.

**Dykman, R.A.**; *see* Karson, C.N.

### E

**Erlenmeyer-Kimling, L.**; *see* Weeks, D.E.

### F

**Farmer, A.**; McGuffin, P.; and Gottesman, I.I. Problems and pitfalls of the family history positive and negative dichotomy: Response to Dalén, 16(3):367-370, 1990.

**Feinberg, I.** Cortical pruning and the development of schizophrenia (Letter to the Editor), 16(4):567-568, 1990.

**Fenton, W.S.**; *see* McGlashan, T.H.

**Fenyo, A.**; *see* Beecham, J.

**Flaum, M.**; *see* Andreasen, N.C.

**Flaum, M.**, and *Andreasen, N.C.*

Diagnostic criteria for schizophrenia and related disorders: Options for *DSM-IV*, 17(1):133-156, 1991.

**Flor-Henry, P.** Influence of gender in schizophrenia as related to other psychopathological syndromes, 16(2):211-227, 1990.

**Flowers, D.L.**; *see* Wood, F.B.

**Fogg, L.**; *see* Silverstein, M.L.

**Frances, A.**; *see* Dixon, L.

**Freeman, D.H.**; *see* Bartels, S.J.

### G

**Gasperini, M.**; *see* Battaglia, M.

**Gerlach, J.** New antipsychotics: Classification, efficacy, and adverse effects, 17(2):289-309, 1991.

**Giel, R.**; *see* Wiersma, D.

**Gilliam, T.C.**; *see* Weeks, D.E.

**Glick, I.D.**; *see* Haas, G.L.

**Goldberg, D.** Cost-effectiveness studies in the treatment of schizophrenia: A review, 17(3):453-459, 1991.

**Goldman, H.H.**; *see* Ridgely, M.S.

**Goldman-Rakic, P.S.**; *see* Kirch, D.G.

**Goldstein, J.M.**; *see* Angermeyer, M.C.

**Goldstein, J.M.**, and Tsuang, M.T. Gender and schizophrenia: An introduction and synthesis of findings, 16(2):179-183, 1990.

**Goldstein, J.M.**; *see* Santangelo, S.L.; Simpson, J.C.; and Tsuang, M.T. The role of gender in identifying subtypes of schizophrenia: A latent class analytic approach, 16(2):263-275, 1990.

**Goldstein, M.J.**; *see* Brenner, H.D.

**Gorman, J.M.**; *see* Amador, X.F.

**Gottesman, I.I.**; *see* Caldwell, C.B.; Farmer, A.; Vinogradov, S.

**Green, M.F.**, and Kinsbourne, M. Subvocal activity and auditory hallucinations: Clues for behavioral treatments?, 16(4):617-625, 1990.

**Grove, W.M.**; Lebow, B.S.; and Medus, C. Head size in relation to schizophrenia and schizotypy, 17(1):157-161, 1991.

**Gulley, L.R.**; *see* Lewine, R.R.J.

**Gur, R.C.**; *see* Gur, R.E.

**Gur, R.E., and Gur, R.C.** Gender differences in regional cerebral blood flow, 16(2):247-254, 1990.

**Gur, R.E.**; Gur, R.C.; and Saykin, A.J. Neurobehavioral studies in schizophrenia: Implications for regional brain dysfunction, 16(3):445-451, 1990.

**Gutheil, T.G.**; *see* Cassens, G.

**H**

**Haas, G.**; *see* Dixon, L.

**Haas, G.L.**; Glick, I.D.; Clarkin, J.F.; Spencer, J.H.; and Lewis, A.B. Gender and schizophrenia outcome: A clinical trial of an inpatient family intervention, 16(2):277-292, 1990.

**Häfner, H.**, and an der Heiden, W. Evaluating effectiveness and cost of community care for schizophrenic patients, 17(3):441-451, 1991.

**Harding, C.M.**; *see* Childers, S.E.

**Harrison, G.** Searching for the causes of schizophrenia: The role of migrant studies, 16(4):663-671, 1990.

**Harvey, P.D.**; Docherty, N.M.; Serper, M.R.; and Rasmussen, M. Cognitive deficits and thought disorder: II. An 8-month followup study, 16(1):147-156, 1990.

**Heh, C.**; *see* Jin, Y.

**Herlich, A.J.** Evidence for reduced and dysregulated turnover of dopamine in schizophrenia, 16(4):605-615, 1990.

**Higenbottam, J.**; *see* Koczapski, A.B.

**Hoffman, R.E., and Dobcska, S.K.** Reduced cortico-cortical exchange of information as a possible etiology of schizophrenia—Reply to Feinberg (Letter to the Editor), 16(4):569-570, 1990.

**Holmes-Eber, P.**, and Riger, S. Hospitalization and the composition of mental patients' social networks, 16(1):157-164, 1990.

**Houpt, J.L.**; *see* Lewine, R.R.J.

**Hu, T.**, and Jerrell, J. Cost-effectiveness of alternative approaches in treating severely mentally ill in California, 17(3):461-468, 1991.

**Hubbard, J.W.**; *see* Brenner, H.D.

**Hurlbut, S.C.**; *see* Drake, R.E.

**Hyde, A.P.** Response to "Effects of caffeine on behavior of schizophrenic inpatients," 16(3):371-372, 1990.

**Hyland, B.** First person account: A thousand cloudy days, 17(3):539-545, 1991.

**I**

**Inglis, A.K.**; *see* Cassens, G.

**Isenhart, R.**; *see* Jin, Y.

**J**

**Jatlow, P.I.**; *see* Bowers, M.B., Jr.

**Jerrell, J.**; *see* Hu, T.

**Jewart, R.**; *see* Lewine, R.R.J.

**Jin, Y.**; Potkin, S.G.; Rice, D.; Sramek, J.; Costa, J.; Isenhart, R.; Heh, C.; and Sandman, C.A. Abnormal EEG responses to photic stimulation in schizophrenic patients, 16(4):627-634, 1990.

**Johnson, M.M.**; *see* Josiassen, R.C.

**Josiassen, R.C.**; Roemer, R.A.; Johnson, M.M.; and Shagass, C. Are gender differences in schizophrenia reflected in brain event-related potentials?, 16(2):229-246, 1990.

**K**

**Kane, J.M.** New developments in the pharmacologic treatment of schizophrenia: Editor's introduction, 17(2):193-195, 1991; Obstacles to clinical research and new drug development in schizophrenia, 17(2):353-356, 1991; *see also* Saffer, A.; Szymanski, S.

**Kane, J.M., and Selzer, J.** Considerations on "organic" exclusion criteria for schizophrenia, 17(1):69-73, 1991.

**Kaplan, I.**; *see* McGorry, P.D.

**Karson, C.N.**; Dykman, R.A.; and Paige, S.R. Blink rates in schizophrenia, 16(2):345-354, 1990.

**Kasten, A.M.**; *see* Rosenson, M.K.

**Kay, S.R.** Significance of the positive-negative distinction in schizophrenia, 16(4):635-652, 1990; *see also* Sandyk, R.

**Kay, S.R., and Sevy, S.** Pyramidal model of schizophrenia, 16(3):537-545, 1990.

**Kee, K.**; *see* Mueser, K.T.

**Keegan, D.L.**; *see* Brenner, H.D.

**Keith, S.J., and Matthews, S.M.** The diagnosis of schizophrenia: A review of onset and duration issues, 17(1):51-67, 1991.

**Kinon, B.J.**; *see* Lieberman, J.A.; Saffer, A.

**Kinsbourne, M.**; *see* Green, M.F.

**Kirch, D.G.**; *see* Christison, G.W.

**Kirch, D.G.**; Wagman, A.M.I.; and Goldman-Rakic, P.S. Commentary: The acquisition and use of human brain tissue in neuropsychiatric research, 17(4):593-596, 1991.

**Kluiter, H.**; *see* Wiersma, D.

**Knapp, M.**; *see* Beecham, J.

**Koczapski, A.B.**; Ledwidge, B.; Paredes, J.; Kogan, C.; and Higenbottam, J. Multisubstance intoxication among schizophrenic inpatients: Reply to Hyde, 16(3):373-375, 1990.

**Kogan, C.**; *see* Koczapski, A.B.

**Kopala, L., and Clark, C.** Implications of olfactory agnosia for understanding sex differences in

schizophrenia, 16(2):255-261, 1990.

Kruger, G.; *see* Brenner, H.D.

Kühn, L.; *see* Angermeyer, M.C.

Kulhanek, F.; *see* Brenner, H.D.

## L

Lang, M.; *see* Seeman, M.V.

Lebow, B.S.; *see* Grove, W.M.

Ledwidge, B.; *see* Koczapski, A.B.

Lehner, T.; *see* Weeks, D.E.

Lenzenweger, M.F.; Dworkin, R.H.; and Wethington, E. Examining the underlying structure of schizophrenic phenomenology: Evidence for a three-process model, 17(3):515-524, 1991.

Levinson, D.F., and Mowry, B.J. Defining the schizophrenia spectrum: Issues for genetic linkage studies, 17(3):491-514, 1991.

Levinson, D.F.; *see* Mueser, K.T. Lewine, R.R.J. Reflections on Saugstad's "Social class, marriage, and fertility in schizophrenia," 16(2):171-174, 1990.

Lewine, R.R.J.; Gulley, L.R.; Risch, S.C.; Jewart, R.; and Houpt, J.L. Sexual dimorphism, brain morphology, and schizophrenia, 16(2):195-203, 1990.

Lewis, A.B.; *see* Haas, G.L.

Lewis, M.S. *Res ipsa loquitur*: The author replies, 16(1):17-28, 1990.

Liberman, R.P.; *see* Brenner, H.D.

Liberman, J.A.; *see* Safferman, A.; Szymanski, S.

Liberman, J.A., and Bowers, M.B., Jr. Substance abuse comorbidity in schizophrenia: Editors' introduction, 16(1):29-30, 1990.

Lieberman, J.A.; Kinon, B.J.; and Loebel, A.D. Dopaminergic mechanisms in idiopathic and drug-induced psychoses, 16(1):97-110, 1990.

Lim, K.O.; *see* Pfefferbaum, A.

Loebel, A.D.; *see* Lieberman, J.A.

Malm, U.; *see* Brenner, H.D.

Marder, S.R.; *see* Van Putten, T.

Marengo, J.T.; *see* Silverstein, M.L.

Matthews, S.M.; *see* Keith, S.J.

Mazure, C.M.; *see* Bowers, M.B., Jr.

McCulloch, P.B.; *see* Witelson, S.F.

McGlashan, T.H., and Bardenstein, K.K. Gender differences in affective, schizoaffective, and schizophrenic disorders, 16(2):319-329, 1990.

McGlashan, T.H., and Fenton, W.S. Classical subtypes for schizophrenia: Literature review for *DSM-IV*, 17(4):609-624, 1991.

McGorry, P.D.; Copolov, D.L.; and

Singh, B.S. Royal Park Multidiagnostic Instrument for Psychosis: Part I. Rationale and review, 16(3):501-515, 1990.

McGorry, P.D.; Singh, B.S.; Copolov, D.L.; Kaplan, I.; Dossetor, C.R.; and van Riel, R.J. Royal Park Multidiagnostic Instrument for Psychosis: Part II. Development, reliability, and validity, 16(3):517-536, 1990.

McGrath, J.A.; *see* Pulver, A.E.

McGuffin, P.; *see* Farmer, A.

McGuire, T.G. Measuring the economic costs of schizophrenia, 17(3):375-388, 1991.

Medus, C.; *see* Grove, W.M.

Meltzer, H.Y. Commentary: Defining treatment refractoriness in schizophrenia, 16(4):563-565, 1990; The mechanism of action of novel antipsychotic drugs, 17(2):263-287, 1991.

Merskey, H. Sluggish schizophrenia (Letter to the Editor), 17(4):553, 1991.

Mezzich, J.E. Architecture of clinical information and prediction of service utilization and cost, 17(3):469-474, 1991.

Midha, K.K.; *see* Brenner, H.D.

Moises, H.W.; *see* Vinogradov, S.

Moorman, C.C.; *see* Pulver, A.E.

Morrison, R.L.; *see* Mueser, K.T.

Moscarelli, M., and Capri, S. The cost of schizophrenia: Editors' introduction, 17(3):367-373, 1991.

Moscarelli, M.; Capri, S.; and Neri, L. Cost evaluation of chronic schizophrenic patients during the first 3 years after the first contact, 17(3):421-426, 1991.

Mowry, B.J.; *see* Levinson, D.F.

Mueser, K.T.; Douglas, M.S.; Bellack, A.S.; and Morrison, R.L. Assessment of enduring deficit and negative symptom subtypes in schizophrenia, 17(4):565-582, 1991.

Mueser, K.T.; Yarnold, P.R.; Levinson, D.F.; Singh, H.; Bellack, A.S.; Kee, K.; Morrison, R.L.; and Yadalam, K.G. Prevalence of substance abuse in schizophrenia: Demographic and clinical correlates, 16(1):31-56, 1990.

## N

Nasrallah, H.A.; Schwarzkopf, S.B.; Olson, S.C.; and Coffman, J.A. Gender differences in schizophrenia on MRI brain scans, 16(2):205-210, 1990.

Nelson, J.C.; *see* Bowers, M.B., Jr.

Neri, L.; *see* Moscarelli, M.

Nicol, S.; *see* Vinogradov, S.

Nienhuis, F.J.; *see* Wiersma, D.

Noordsy, D.L.; *see* Drake, R.E.

## O

Olson, S.C.; *see* Nasrallah, H.A.

Osher, F.C.; *see* Drake, R.E.

Ott, J.; *see* Weeks, D.E.

## P

Paige, S.R.; *see* Karson, C.N.

Paredes, J.; *see* Koczapski, A.B.

Pfefferbaum, A.; Lim, K.O.; Rosenblum, M.; and Zipursky, R.B. Brain magnetic resonance imaging: Approaches for investigating schizophrenia, 16(3):453-476, 1990.

Plasky, P. Antidepressant usage in schizophrenia, 17(4):649-657, 1991.

Potkin, S.G.; *see* Jin, Y.

Pulver, A.E.; Moorman, C.C.; Brown, C.H.; McGrath, J.A.; and Wolyniec, P.S. Age-incidence artifacts do not account for the season-of-birth effect in schizophrenia, 16(1):13-15, 1990.

**R**

Raftery, J.; *see* Burns, T.

Raine, A. The SPQ: A scale for the assessment of schizotypal personality based on *DSM-III-R* criteria, 17(4):555-564, 1991.

Rasmussen, M.; *see* Harvey, P.D.

Rice, D.; *see* Jin, Y.

Ridgely, M.S.; Goldman, H.H.; and Willenbring, M. Barriers to the care of persons with dual diagnoses: Organizational and financing issues, 16(1):123-132, 1990.

Riger, S.; *see* Holmes-Eber, P.

Risch, S.C.; *see* Lewine, R.R.J.

Robbins, T.W. The case for fronto-striatal dysfunction in schizophrenia, 16(3):391-402, 1990.

Roemer, R.A.; *see* Josiassen, R.C.

Rogers, J.A., and Centifanti, J.B. Beyond "self-paternalism": Response to Rosenson and Kasten, 17(1):9-14, 1991.

Rosenbloom, M.; *see* Pfefferbaum, A.

Rosenson, M.K., and Kasten, A.M. Another view of autonomy: Arranging for consent in advance, 17(1):1-7, 1991.

Rotov, M. Phenomenology or physicalism?, 17(2):183-186, 1991.

Ruocchio, P.J. First person account: The schizophrenic inside, 17(2):357-360, 1991.

Rüphan, M.; *see* Wiersma, D.

Rupp, A. Underinsurance for severe mental illness, 17(3):401-405, 1991.

**S**

Safferman, A.; Lieberman, J.A.; Kane, J.M.; Szymanski, S.; and Kinon, B. Update on the clinical efficacy and side effects of clozapine, 17(2):247-261, 1991.

Sandman, C.A.; *see* Jin, Y.

Sandyk, R., and Kay, S.R. Pineal melatonin in schizophrenia: A review and hypothesis, 16(4):653-662, 1990.

Santangelo, S.L.; *see* Goldstein, J.M.

Sartorius, N., and de Girolamo, G. Preface, 17(3):371-373, 1991.

Saugstad, L.F. Social class, marriage, and fertility in schizophrenia: The author replies, 16(2):175-178, 1990.

Saykin, A.J.; *see* Gur, R.E.

Scherillo, P.; *see* Battaglia, M.

Schooler, N.R. Maintenance medication for schizophrenia: Strategies for dose reduction, 17(2):311-324, 1991.

Schöttner, B.; *see* Wiedl, K.H.

Schwarzkopf, S.B.; *see* Nasrallah, H.A.

Sciuto, G.; *see* Battaglia, M.

Seeman, M.V., and Lang, M. The role of estrogens in schizophrenia: gender differences, 16(2):185-194, 1990.

Selzer, J.; *see* Kane, J.M.

Serper, M.R.; *see* Harvey, P.D.

Sevy, S.; *see* Kay, S.R.

Shagass, C.; *see* Josiassen, R.C.

Sharfstein, S.S. Prospective cost allocations for the chronic schizophrenic patient, 17(3):395-400, 1991.

Silverstein, M.L.; Marengo, J.T.; and Fogg, L. Two types of thought disorder and lateralized neuropsychological dysfunction, 17(4):679-687, 1991.

Simpson, J.C.; *see* Goldstein, J.M.

Singer-Sam, J. An epigenetic role in schizophrenia (Letter to the Editor), 17(3):365, 1991.

Singh, B.S.; *see* McGorry, P.D.

Siris, S.G. Diagnosis of secondary depression in schizophrenia: Implications for *DSM-IV*, 17(1):75-98, 1991; Pharmacological treatment of substance-abusing schizophrenic patients, 16(1):111-122, 1990.

Smith, E. First person account: Living with schizophrenia, 17(4):689-691, 1991.

Sorensen, I.; *see* Benes, F.M.

Spencer, J.H.; *see* Haas, G.L.

Squires-Wheeler, E.; *see* Weeks, D.E.

Sramek, J.; *see* Jin, Y.

Stefanovich, M.; *see* Weeks, D.E.

Strauss, D.H.; *see* Amador, X.F.

Struening, E.L.; *see* Susser E.S.

Stuss, D.T.; *see* Benson, D.F.

Susser, E.S., and Struening, E.L. Diagnosis and screening for psychotic disorders in a study of the homeless, 16(1):133-145, 1990.

Sweeney, J.; *see* Dixon, L.

Szymanski, S.; *see* Safferman, A.

Szymanski, S.; Kane, J.M.; and Lieberman, J.A. A selective review of biological markers in schizophrenia, 17(1):99-111, 1991.

**T**

Teague, G.B.; *see* Drake, R.E.

Test, M.A.; Burke, S.S.; and Wallich, L.S. Gender differences of young adults with schizophrenic disorders in community care, 16(2):331-344, 1990.

Torrey, E.F. A viral-anatomical explanation of schizophrenia, 17(1):15-18, 1991.

Torrey, E.F., and Bowler, A. Geographical distribution of insanity in America: Evidence for an urban factor, 16(4):591-604, 1990.

Torrey, E.F., and Bowler, A.E. The seasonality of schizophrenic births: A reply to Marc S. Lewis, 16(1):1-3, 1990.

Tsuang, M.T.; *see* Goldstein, J.M.; Turner, W.M.

Turner, W.M., and Tsuang, M.T. Impact of substance abuse on the

course and outcome of schizophrenia, 16(1):87-95, 1990.

**V**

Van Putten, T.; Marder, S.R.; Wirshing, W.C.; Aravagiri, M.; and Chabert, N. Neuroleptic plasma levels, 17(2):197-216, 1991.  
 van Riel, R.J.; *see* McGorry, P.D.  
 Vinogradov, S.; Gottesman, I.I.; Moises, H.W.; and Nicol, S. Negative association between schizophrenia and rheumatoid arthritis, 17(4):669-678, 1991.

**W**

Wagman, A.M.I.; *see* Kirch, D.G.  
 Waldo, M.C.; *see* Adler, L.E.  
 Wallach, M.A.; *see* Bartels, S.J.  
 Wallisch, L.S.; *see* Test, M.A.  
 Watson, C.G. Schizophrenic birth seasonality and the age-incidence

artifact, 16(1):5-10, 1990.

Weeks, D.E.; Brzustowicz, L.; Squires-Wheeler, E.; Cornblatt, B.; Lehner, T.; Stefanovich, M.; Bassett, A.; Gilliam, T.C.; Ott, J.; and Erlenmeyer-Kimling, L. Report of a workshop on genetic linkage studies in schizophrenia, 16(4):673-686, 1990.  
 Weiden, P.; *see* Dixon, L.  
 Wethington, E.; *see* Lenzenweger, M.F.  
 Wiedl, K.H., and Schöttner, B. Coping with symptoms related to schizophrenia, 17(3):525-538, 1991.

Wiersma, D.; Kluiter, H.; Nienhuis, F.J.; Rüphan, M.; and Giel, R. Costs and benefits of day treatment with community care for schizophrenic patients, 17(3):411-419, 1991.

Willenbring, M.; *see* Ridgely, M.S.  
 Wirshing, W.C.; *see* Van Putten, T.  
 Witelson, S.F., and McCulloch, P.B.

Premortem and postmortem measurement to study structure with function: A human brain collection, 17(4):583-591, 1991.

Wolyniec, P.S.; *see* Pulver, A.E.  
 Wood, F.B., and Flowers, D.L. Hypofrontal vs. hypo-Sylvian blood flow in schizophrenia, 16(3):413-424, 1990.

Wyatt, R.J. Neuroleptics and the natural course of schizophrenia, 17(2):325-351, 1991. *see also* Christison, G.W.

**Y**

Yadalam, K.G.; *see* Mueser, K.T.  
 Yale, S.A.; *see* Amador, X.F.  
 Yarnold, P.R.; *see* Mueser, K.T.

**Z**

Zipursky, R.B.; *see* Pfefferbaum, A.

## Subject Index

### A

#### Age factors

Age-incidence effect clarification, 16:13  
 Age of onset and gender differences, 16:211  
 Seasonality and age-incidence effect, 16:1, 16:5, 16:11, 16:17

Alcohol. *See also* Substance abuse comorbidity

Alcohol use disorders assessment instrument is needed, 16:57

#### Antihistamines

Intoxication-related behavior patterns, 16:373

Antipsychotic drugs. *See* Neuroleptics; Treatment

#### Auditory hallucinations

Relationship to subvocal activity, 16:617

#### Auditory sensory gating

Hippocampal abnormality and auditory sensory gating, 17:19

#### Autobiographical accounts. *See also*

Subjective experiences  
 Coping strategies, 16:547  
 Course of illness description, 16:165  
 Inside view of illness, 17:357  
 Mother's view of daughter's illness, 17:689  
 Mother's view of son's illness, 16:687, 17:539  
 Psychotic episode and hospitalization, 16:355  
 Treatment of the chronically mentally ill, 17:173

**B**

#### Behavior

Caffeine sensitivity, 16:371  
 Hostility variables identified, 17:163

---

**Intoxication-related behavior patterns, 16:373**

**Neurobehavioral studies of frontal and temporal lobe dysfunction, 16:445**

**Biological markers**

Studies needed to develop trait markers, 17:99

**Biological psychiatry**

Criticism of the underlying assumptions, 17:183

**Brain areas**

Frontal lobes, basal ganglia, and temporal lobes, 16:377, 16:379

Frontal lobe influences on delusions, 16:403

Posterior hippocampus neuronal size, 17:597

Right- and left-hemisphere neuropsychological dysfunction, 17:679

**Brain development**

Age of onset and gender differences relation to, 16:211

Computer model of cortical pruning, 16:567

Fetal asymmetries, 17:551

Neurodevelopmental model of schizophrenia and manic depressive illness, 16:171, 16:175

Temporal lobe asymmetries, 16:433

**Brain imaging**

Frontal and temporal lobe dysfunction, 16:445

Frontal lobe influences on delusions, 16:403

Frontal lobes, basal ganglia, and temporal lobes, 16:377

Frontostriatal dysfunction hypothesis of schizophrenia, 16:391

Gender differences in regional cerebral blood flow, 16:247

Hypofrontality and hypo-Sylvian blood flow, 16:413

Magnetic resonance imaging, 16:205, 16:453

**Photic stimulation responses and EEG spectra, 16:627**

**Positron emission tomography studies, 16:379**

**Temporal lobe asymmetries, 16:433**

**Brain morphology**

Brain tissue collection issues, 17:593

Sex differences and neuropsychological performance, 16:195

Structure-function relationship postmortem studies, 17:583

**C**

**Caffeine**

Caffeine sensitivity and psychotogenic actions, 16:371

Intoxication-related behavior patterns, 16:373

**Classification**

American-Soviet systems, 17:553

*DSM-III-R* and ICD-10 definition comparison, 17:27

Five criteria sets for *DSM-IV* field trials, 17:143

Introduction to *DSM-IV* proposed changes, 17:25

Role of prodromal and residual symptoms, duration of psychotic symptoms, and the 6-month vs. 1-month criterion, 17:51

Subtype criteria for *DSM-IV*, 17:609

**Cognition**

Manic and schizophrenic patient followup study, 16:147

**Community Adjustment Scale, 16:309**

**Cormorbidity. See Substance abuse comorbidity**

**Coping strategies**

Assessment method, 17:525

Autobiographical account, 16:547

**Course and outcome. See Long-term followup studies**

**Cranial size**

Relation to schizotypal personality disorder and schizophrenia, 17:157

**D**

**Delusions**

Frontal lobe influences, 16:403

Review of research and theoretical work, 17:633

**Deodorants and aerosols**

Intoxication-related behavior patterns, 16:373

**Depression**

Comorbidity and suicide risk, 16:571

Relevance of secondary depression, 17:75

Seasonality issues, 17:191

Tricyclic antidepressant treatment, 17:649

**Diagnosis. See also Classification**

Alcohol use disorders assessment instrument is needed, 16:57

Alternative diagnostic criteria and field trial modifications, methods, and goals, 17:133

American-Soviet classification systems, 17:553

Biological markers identified, 17:99

Criteria sets for *DSM-IV* field trials, 17:143

Historical concepts of "characteristic symptoms," 17:27

Introduction to *DSM-IV* proposed changes, 17:25

National Plan for Schizophrenia Research, 17:183

Organic factor exclusion criteria issues, 17:69

Role of prodromal and residual symptoms, duration of psychotic symptoms, and the 6-month vs. 1-month criterion, 17:51

Subtype criteria, 17:609

**Diagnostic and Statistical Manual**

Criteria sets for *DSM-IV* field trials, 17:143

---

**DSM-III-R and ICD-10 definition comparison, 17:27**

**Introduction to proposed changes in diagnostic criteria, 17:25**

**Subtype criteria for *DSM-IV*, 17:609**

**Dopamine**

- Dopaminergic activity and atypical antipsychotic drugs, 17:263**
- Dopaminergic hyperactivity, 16:605**
- Glutamate-dopamine imbalance, 16:425**

**E**

**Economic factors**

- Assessment procedures to evaluate costs, 17:475**
- Budgeting costs of treatment for chronic patients, 17:395**
- Community-based treatment, case-management approaches, and capitation funding, 17:461**
- Community care and hospitalization cost-effectiveness comparison, 17:453**
- Community care cost-effectiveness evaluation, 17:441**
- Cost of mental illness and schizophrenia for 1955 and 1985, 17:367**
- Cost variables and outcome, 17:427**
- Costs associated with improper measurement and unreliability, 17:483**
- Day treatment costs and benefits, 17:411**
- Home-based and standard care comparison, 17:407**
- Incidence-based costing algorithm, 17:389**
- Overview of cost of illness, 17:367**
- Prediction of service utilization and cost, 17:469**
- Three-year costs of chronic schizophrenic patients, 17:421**
- Uninsurance and underinsurance issues, 17:401**

**Environmental factors**

- Migrant studies and environmental factor determination, 16:663**

**Epidemiology**

- Negative association between rheumatoid arthritis and schizophrenia, 17:669**
- Season of birth, 16:1, 16:5, 16:11, 16:13, 16:17**
- Secondary depression occurrence, 17:75**
- Substance abuse comorbidity, 16:29, 16:31**
- Urban factor of geographical distribution of insanity, 16:591**

**Etiology. *See also Diagnosis***

- Auditory sensory gating and hippocampal structure abnormality, 17:19**
- Family history positive vs. family history negative, 16:367**
- Frontostriatal dysfunction hypothesis, 16:391**
- Neurotransmitter imbalance, 16:425**
- Organic factor exclusion criteria issues, 17:69**
- Temporal lobe asymmetries, 16:433**
- Viral infections and schizophrenia, 17:15**

**Event-related brain potentials**

- Influences of gender on, 16:229**

**F**

**Families**

- Cranial size relation to schizotypal personality disorder and schizophrenia in siblings, 17:157**
- Family history positive vs. family history negative, 16:367**
- Family response to inpatient family intervention, 16:277**
- Gender differences in risk and development of schizophrenia, 16:263**
- Genetic linkage studies, 17:491**
- Morbidity risk for schizophrenia in schizotypal patients, 17:659**

**G**

**Gender differences**

- Age of onset and gender differences in relation to brain development, 16:211**
- Clinical profiles and long-term outcomes in Chestnut Lodge study participants, 16:319**
- Course and outcome studies, 16:293**
- Estrogen role, 16:185**
- Influences of gender on event-related brain potentials, 16:229**
- Introduction and synthesis of findings, 16:179**
- MRI study of cerebral structures, 16:205**
- Olfactory agnosia, 16:255**
- Premorbid social functioning, gender, and long-term outcome relationships, 16:309**
- Regional cerebral blood flow studies, 16:247**
- Risk differences for developing different subtypes of schizophrenia, 16:263**
- Role functioning differences, 16:277**
- Suicide risk, 16:571**
- Young adults in progressive community care, 16:331**

**Genetic factors**

- Diminished melatonin secretion as marker, 16:653**
- Epigenic role, 17:365**
- Familial/sporadic subdivision use as clinical research method, 16:363**
- Genetic linkage studies, 17:491**
- Genetic linkage studies workshop report, 16:673**
- Hippocampal abnormality and auditory sensory gating, 17:19**
- Temporal lobe asymmetries, 16:433**

**Glutamate**

- Role in control of psychomotor activity, 16:425**

**Grants**

- Schizophrenia-related grants, fiscal year 1989, 16:691
- Schizophrenia-related grants, fiscal year 1990, 17:693

**H**

**Homeless persons**

- Screening scales for psychotic symptoms, 16:133

**Hormones**

- Estrogen role in gender differences, 16:185

**Hospitalization**

- Effect on social network size and composition, 16:157
- "Hostel ward" alternative, 17:453

**Hostility**

- Six variables identified, 17:163

**Hyperventilation**

- Intoxication-related behavior patterns, 16:373

**Hypofrontality**

- Hypo-Sylvian blood flow comparison, 16:413

**I**

**Insurance**

- Uninsurance and underinsurance issues, 17:401

**International Classification of Diseases**

- DSM-III-R and ICD-10 definition comparison, 17:27

**L**

**Legal issues**

- Prior consent agreements and patient's right to refuse treatment, 17:1, 17:9

**Long-term followup studies**

- Community-based treatment, case-management approaches, and capitation funding, 17:461
- Community care and hospitalization cost-effectiveness evaluation, 17:453
- Cost variables and outcome, 17:427

**Day treatment costs and benefits, 17:411**

**Gender differences in Chestnut Lodge study participants, 16:319**

**Gender differences in course and outcome, 16:293**

**Gender differences in young adults study of progressive community care, 16:331**

**Manic and schizophrenic patient followup, 16:147**

**Neuroleptics and natural course of schizophrenia, 17:325**

**Premorbid social functioning, gender, and long-term outcome relationships, 16:309**

**Substance abuse impact on course and outcome, 16:87**

**M**

**Magnetic resonance imaging**

- Frontal lobes, temporal lobes, and basal ganglia, 16:453
- Gender differences, 16:205

**Migrant studies**

- Role in environmental factor determination, 16:663

**Molecular biology**

- Negative association between rheumatoid arthritis and schizophrenia, 17:669

**N**

**National Plan for Schizophrenia Research**

- Clinical phenomenology, 17:183

**Negative syndromes**

- Measurement and assessment, 16:635

**Neuroleptics**

- Clozapine efficacy and side effects, 17:247
- Effects on neuropsychological function in chronic cases, 16:477
- Natural course of schizophrenia studies, 17:325
- Plasma level variations, 17:197
- Psychotogenic drug use effect on neuroleptic response, 16:81

**Treatment alternatives for neuroleptic-resistant patients, 17:217**

**Tricyclic antidepressants used with neuroleptics for depression treatment, 17:649**

**Neuropathology**

- Blink-alpha neurocircuit, 16:345

**Neuropsychology**

- Effects of neuroleptics on neuropsychological function in chronic cases, 16:477
- Sex differences in brain morphology and neuropsychological performance, 16:195

**Neurotransmitters**

- Dopamine-glutamate imbalance, 16:425

**Nicotine**

- Intoxication-related behavior patterns, 16:373

**O**

**Olfactory agnosia, 16:255**

**Organic factor**

- Exclusion criteria issues, 17:69

**Outcome. See Long-term followup studies**

**P**

**Patient rights**

- Prior consent agreements and patient's right to refuse treatment, 17:1, 17:9

**Phenomenology**

- Criticism of the underlying assumptions of "Biological Psychiatry," 17:183
- History of the term, 17:187
- Three-process model for structure of schizophrenic phenomenology, 17:515

**Pineal gland**

- Diminished melatonin secretion as marker, 16:653

---

**Positive syndromes**  
 Measurement and assessment, 16:635

**Positron emission tomography**  
 Frontal lobe, basal ganglia, and temporal lobe studies, 16:379

**Premorbid Adjustment Scale**, 16:309

**Prognosis.** *See* Long-term followup studies

**Psychiatric Epidemiology Research Instrument**, 16:133

**Psychomotor activity**  
 Glutamate role, 16:425

**R**

**Research design and methodology**  
 Age incidence can be a source of error, 16:11

Brain structure-function relationship postmortem studies, 17:583

Brain tissue collection issues, 17:593

Clarification of age-incidence effect, 16:13

Community care cost-effectiveness evaluation, 17:441

Cost variables and outcome, 17:427

Delusions, 17:633

Dose reduction methods review, 17:311

Familial/sporadic subdivisions, 16:363

Field trials of diagnostic criteria, 17:133

Genetic linkage studies, 17:491

Incidence-based costing algorithm, 17:389

Methodological issues in assessing prevalence of substance abuse comorbidity, 16:31

Migrant studies and environmental factor determination, 16:663

Neurodevelopmental model of schizophrenia and manic depressive illness, 16:171, 16:175

Obstacles to treatment research, 17:353

**Organic factor exclusion criteria issues**, 17:69

**Positive and negative syndrome research**, 16:635

**Prediction of service utilization and cost**, 17:469

**Quantitative morphometric techniques to study posterior hippocampus neuronal size**, 17:597

**Screening for psychotic symptoms in community studies**, 16:133

**Seasonality and age-incidence effect**, 16:17

**Seasonality result of design problems or age-incidence effect**, 16:5

**Substance abuse impact on course and outcome design and method suggestions**, 16:87

**Three-process model for structure of schizophrenic phenomenology**, 17:515

**Rheumatoid arthritis**  
 Negative association between rheumatoid arthritis and schizophrenia, 17:669

**Royal Park Multidiagnostic Instrument for Psychosis**  
 Development and structure, 16:517  
 Rationale and review, 16:501

**S**

**Scales**  
 Assessment method for coping strategies, 17:525  
 Community Adjustment Scale, 16:309  
 Premorbid Adjustment Scale, 16:309  
 Psychiatric symptom scale suggests pyramidal model, 16:537  
 Quality of Life Scale, 17:565  
 Royal Park Multidiagnostic Instrument for Psychosis, 16:501, 16:517  
 Scale for the Assessment of Negative Symptoms, 17:565  
 Schedule for Schizotypal Personalities interview, 17:157

**Schizotypal Personality Questionnaire**, 17:555

**Screening for psychotic symptoms in community studies**, 16:133

**Schedule for Schizotypal Personalities interview**, 17:157

**Schizoaffective disorder**  
 Clinical profiles and long-term outcomes in Chestnut Lodge study participants, 16:319

**Schizotypal personality disorder**  
 Assessment scale, 17:555  
 Cranial size relationship, 17:157  
 Morbidity risk for schizophrenia, 17:659

**Schizotypal Personality Questionnaire**, 17:555

**Season of birth**  
 Age incidence in season-of-birth studies, 16:11  
 Clarification of age-incidence effect, 16:13  
 Seasonality and age-incidence effect, 16:1, 16:17  
 Seasonality of schizophrenia and of depressive episodes, 17:191  
 Seasonality result of design problems or age-incidence effect, 16:5

**Self-awareness deficits.** *See* Unawareness of illness

**Social functioning**  
 Premorbid social functioning, gender, and long-term outcome relationships, 16:309

**Social networks**  
 Effect of hospitalization on network size and composition, 16:157

**Socioeconomic factors**  
 Regional correlation of schizophrenia with, 16:591

**Statistical issues.** *See also* Research design and methodology  
 Reliability, measurements, and costs, 17:483

**Season-of-birth studies**, 16:1, 16:5, 16:11, 16:13, 16:17

**Stimulants**  
Impact of stimulant use on schizophrenia, 16:97

**Structured Clinical Interview for DSM-III-R: Psychotic Disorders**, 16:133

**Subjective experiences**  
Acute intoxication, 16:69

**Substance abuse comorbidity**  
Acute intoxication, 16:69  
Alcohol use disorders are common comorbid conditions, 16:57  
Editors' overview, 16:29  
Methodological issues in assessing prevalence, 16:31  
Organizing and financing care of patients with comorbidities, 16:123  
Pharmacological treatment, 16:111  
Psychotogenic drug use effect on neuroleptic response, 16:81  
Stimulant abuse, 16:97

**Suicide**  
Risk factor review, 16:571

**Symptoms**  
Enduring negative and deficit symptoms, 17:565  
Historical concepts of "characteristic symptoms," 17:27  
Role of prodromal and residual symptoms, duration of psychotic symptoms, and the 6-month vs. 1-month criterion, 17:51  
Secondary depression, 17:75

**T**  
**Tardive dyskinesia**  
Dose reduction issues, 17:311

**Thought disorder**  
Manic and schizophrenic patient

**followup study, 16:147**  
**Right- and left-hemisphere neuropsychological dysfunction, 17:679**

**Treatment**  
Action of atypical antipsychotic drugs, 17:263  
Antipsychotics reviewed for efficacy and adverse effects, 17:289  
Behavioral interventions for auditory hallucinations, 16:617  
Budgeting costs of treatment for chronic patients, 17:395  
Clozapine clinical efficacy and side effects, 17:247  
Community-based treatment, case-management approaches, and capitation funding, 17:461  
Community care and hospitalization cost-effectiveness evaluation, 17:453  
Community care cost-effectiveness evaluation, 17:441  
Cost of mental illness and schizophrenia for 1955 and 1985, 17:367  
Day treatment costs and benefits, 17:411  
Defining refractoriness, 16:551, 16:563  
Dose reduction and tardive dyskinesia risk, 17:311  
Effects of neuroleptics on neuropsychological function in chronic cases, 16:477  
Home-based and standard care comparison, 17:407  
Inpatient family intervention, 16:277  
Neuroleptic plasma level variations in patients, 17:197

**Neuroleptic-resistant patient alternatives, 17:217**  
**Neuroleptics and natural course of schizophrenia studies, 17:325**  
**Organizing and financing care of patients with comorbidities, 16:123**  
**Overview of pharmacological treatments, 17:193**  
**Pharmacological treatment of substance abuse, 16:111**  
**Prior consent agreements and patient's right to refuse the treatment, 17:1, 17:9**  
**Research and new drug development obstacles, 17:353**  
**Secondary depression, 17:75**  
**Tricyclic antidepressant treatment for depression, 17:649**  
**Uninsurance and underinsurance issues, 17:401**

**U**  
**Unawareness of illness**  
Review of literature and assessment guidelines, 17:113

**Unipolar affective disorder**  
Clinical profiles and long-term outcomes in Chestnut Lodge study participants, 16:319

**Urbanization**  
Regional correlation of insanity/schizophrenia with, 16:591

**V**  
**Viral infections**  
Viruses in cranial cavity may cause schizophrenia symptoms, 17:15

**W**  
**Water**  
Intoxication-related behavior patterns, 16:373